MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential

References

• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373(17):1627-39; PMID:26412456; http://dx.doi.org/10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373(2):123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs 2011; 71(8):1093-104; PMID:21668044; http://dx.doi.org/10.2165/11594010-000000000-00000
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2015; 387(10027):1540-50; PMID:26712084; http://dx.doi.org/10.1016/S0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373(19):1803-13; PMID:26406148; http://dx.doi.org/10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16(8):908-18; PMID:26115796; http://dx.doi.org/10.1016/S1470-2045(15)00083-2
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16(3):257-65; PMID:25704439; http://dx.doi.org/10.1016/S1470-2045(15)70054-9
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387(10031):1909-20; PMID:26952546; http://dx.doi.org/10.1016/S0140-6736(16)00561-4
   PubMed Web of Science ®Google Scholar
• Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4):375-84; PMID:25795410; http://dx.doi.org/10.1016/S1470-2045(15)70076-8
   PubMed Web of Science ®Google Scholar
• Clouthier DL, Watts TH. Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection. Cytokine Growth Factor Rev 2014; 25(2):91-106; PMID:24484736; http://dx.doi.org/10.1016/j.cytogfr.2013.12.003
   PubMed Web of Science ®Google Scholar
• Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 2013; 1(5):320-31; PMID:24416730; http://dx.doi.org/10.1158/2326-6066.CIR-13-0086
   PubMed Web of Science ®Google Scholar
• Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 2012; 24(2):217-24; PMID:22245556; http://dx.doi.org/10.1016/j.coi.2011.12.011
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013; 210(9):1685-93; PMID:23897982; http://dx.doi.org/10.1084/jem.20130573
   PubMed Web of Science ®Google Scholar
• Dam J, Schuck P. Calculating sedimentation coefficient distributions by direct modeling of sedimentation velocity concentration profiles. Methods Enzymol 2004; 384:185-212; PMID:15081688; http://dx.doi.org/10.1016/S0076-6879(04)84012-6
   PubMed Web of Science ®Google Scholar
• Chattopadhyay K, Ramagopal UA, Mukhopadhaya A, Malashkevich VN, Dilorenzo TP, Brenowitz M, Nathenson SG, Almo SC. Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function. Proc Natl Acad Sci U S A 2007; 104(49):19452-7; PMID:18040044; http://dx.doi.org/10.1073/pnas.0709264104
   PubMed Web of Science ®Google Scholar
• Zhou Z, Song X, Berezov A, Zhang G, Li Y, Zhang H, Murali R, Li B, Greene MI. Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc Natl Acad Sci U S A 2008; 105(14):5465-70; PMID:18378892; http://dx.doi.org/10.1073/pnas.0711350105
   PubMed Web of Science ®Google Scholar
• Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol 2009; 183(3):1851-61; PMID:19596991; http://dx.doi.org/10.4049/jimmunol.0802597
   PubMed Web of Science ®Google Scholar
• Feinberg H, Powlesland AS, Taylor ME, Weis WI. Trimeric structure of langerin. J Biol Chem 2010; 285(17):13285-93; PMID:20181944; http://dx.doi.org/10.1074/jbc.M109.086058
   PubMed Web of Science ®Google Scholar
• Garcia P, Ucurum Z, Bucher R, Svergun DI, Huber T, Lustig A, Konarev PV, Marino M, Mayans O. Molecular insights into the self-assembly mechanism of dystrophia myotonica kinase. FASEB J 2006; 20(8):1142-51; PMID:16770013; http://dx.doi.org/10.1096/fj.05-5262com
   PubMed Web of Science ®Google Scholar
• Kammerer RA, Kostrewa D, Progias P, Honnappa S, Avila D, Lustig A, Winkler FK, Pieters J, Steinmetz MO. A conserved trimerization motif controls the topology of short coiled coils. Proc Natl Acad Sci U S A 2005; 102(39):13891-6; PMID:16172398; http://dx.doi.org/10.1073/pnas.0502390102
   PubMed Web of Science ®Google Scholar
• Dames SA, Kammerer RA, Wiltscheck R, Engel J, Alexandrescu AT. NMR structure of a parallel homotrimeric coiled coil. Nat Struct Biol 1998; 5(8):687-91; PMID:9699631; http://dx.doi.org/10.1038/90444
   PubMedGoogle Scholar
• Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, Collins M, Shevach EM. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 2004; 173(8):5008-20; PMID:15470044; http://dx.doi.org/10.4049/jimmunol.173.8.5008
   PubMed Web of Science ®Google Scholar
• Ephrem A, Epstein AL, Stephens GL, Thornton AM, Glass D, Shevach EM. Modulation of Treg cells/T effector function by GITR signaling is context-dependent. Eur J Immunol 2013; 43(9):2421-9; PMID:23722868; http://dx.doi.org/10.1002/eji.201343451
   PubMed Web of Science ®Google Scholar
• Ji HB, Liao G, Faubion WA, Abadia-Molina AC, Cozzo C, Laroux FS, Caton A, Terhorst C. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol 2004; 172(10):5823-7; PMID:15128759; http://dx.doi.org/10.4049/jimmunol.172.10.5823
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3(2):135-42; PMID:11812990; http://dx.doi.org/10.1038/ni759
   PubMed Web of Science ®Google Scholar
• Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 2013; 1(5):320-31; PMID:24416730; http://dx.doi.org/10.1158/2326-6066.CIR-13-0086
   PubMed Web of Science ®Google Scholar
• Chattopadhyay K, Ramagopal UA, Nathenson SG, Almo SC. 1.8 A structure of murine GITR ligand dimer expressed in Drosophila melanogaster S2 cells. Acta Crystallogr D Biol Crystallogr 2009; 65(Pt 5):434-9; PMID:19390148; http://dx.doi.org/10.1107/S0907444909005721
   PubMedGoogle Scholar
• Chattopadhyay K, Ramagopal UA, Brenowitz M, Nathenson SG, Almo SC. Evolution of GITRL immune function: murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily. Proc Natl Acad Sci U S A 2008; 105(2):635-40; PMID:18182486; http://dx.doi.org/10.1073/pnas.0710529105
   PubMed Web of Science ®Google Scholar
• Mahrenholz CC, Abfalter IG, Bodenhofer U, Volkmer R, Hochreiter S. Complex networks govern coiled-coil oligomerization–predicting and profiling by means of a machine learning approach. Mol Cell Proteomics 2011; 10(5):M110.004994; PMID:21311038; http://dx.doi.org/10.1074/mcp.M110.004994
   PubMed Web of Science ®Google Scholar
• Sola RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 2010; 24(1):9-21; PMID:20055529; http://dx.doi.org/10.2165/11530550-000000000-00000
   PubMed Web of Science ®Google Scholar
• Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 2013; 73(24):7189-98; PMID:24177180; http://dx.doi.org/10.1158/0008-5472.CAN-12-4174
   PubMed Web of Science ®Google Scholar
• Benevides L, Cardoso CR, Tiezzi DG, Marana HR, Andrade JM, Silva JS. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol 2013; 43(6):1518-28; PMID:23529839; http://dx.doi.org/10.1002/eji.201242951
   PubMed Web of Science ®Google Scholar
• Pedroza-Gonzalez A, Verhoef C, Ijzermans JN, Peppelenbosch MP, Kwekkeboom J, Verheij J, Janssen HL, Sprengers D. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2013; 57(1):183-94; PMID:22911397; http://dx.doi.org/10.1002/hep.26013
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007; 13(15 Pt 1):4345-54; PMID:17671115; http://dx.doi.org/10.1158/1078-0432.CCR-07-0472
   PubMed Web of Science ®Google Scholar
• Leyland R, Watkins A, Mulgrew K, Holoweckyj N, Bamber L, Tigue NJ, Offer E, Andrews J, Yan L, Mullins S et al. A novel murine GITR ligand fusion protein induces antitumor activity as a monotherapy, which is further enhanced in combination with an OX40 agonist. Clin Cancer Res. 2017 Jan 9; PMID:28069723; http://dx.doi.org/10.1158/1078-0432.CCR-16-2000
   PubMedGoogle Scholar